Revenue (Tables)

3 Months Ended

Mar. 31, 2025

Disaggregation of Revenue [Abstract]

Schedule of Revenue Disaggregated by Customer Type

The following table presents the Company's revenue disaggregated by customer type (in thousands):


		Three Months Ended March 31,
		2025				2024
Pharma tests and services (1)		$	13,594			$	9,812
Enterprise sales			2,465				7,972
Population sequencing			4,213				1,500
Clinical diagnostic			308				195
Other			25				46
Total revenue		$	20,605			$	19,525

(1) Includes related party revenue of $0.5 million for the three months ended March 31, 2025.

Schedule of Contract Assets and Liabilities

The opening and closing balances of receivables and contract liabilities from contracts with customers are shown below (in thousands). Contract assets were immaterial for all periods presented.


		March 31, 2025				December 31, 2024
Opening balances:
Accounts receivable, net		$	8,140			$	17,730

Short-term contract liabilities		$	3,100			$	3,288
Long-term contract liabilities (included in other long-term liabilities)			—				3,928
Total contract liabilities			3,100				7,216

Closing balances:
Accounts receivable, net		$	10,973			$	8,140

Short-term contract liabilities		$	1,964			$	3,100
Total contract liabilities			1,964				3,100

Remaining Performance Obligations